CAR-T cell therapies directed against HER2, mesothelin and EGFR are also under investigation in thoracic tumors; however, on-target/off-tumor toxicities, limited trafficking into solid tumor sites, and the highly immunosuppressive TME remain major obstacles. This evidence concerns the gene ERBB2 and neoplasm.